NCT07159763ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
باختصار
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza…
المرحلة 3مطلوب 10,000 مشارك211 موقعاً6 دول
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07159763فتح هذا السجل في ClinicalTrials.govتمت المزامنة أول أمس
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-09-08; recorded start 2025-09-25
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA))
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 181 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A very large study, international in scope: 10,000 participants (target), run at 211 sites, across 6 countries.
How this score is built
- Enrolment38/40
10,000 participants (target)
- Site count25/25
181 sites
- Country count7/15
5 countries
- Planned duration6/10
Planned over about 20 months
- Sponsor scale2/10
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has led 4 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406 (CD388) can help prevent the flu in people who are at higher risk of becoming seriously ill from influenza. Researchers want to find out if MK-1406 dosed at a single study visit can provide protection against influenza compared with placebo. The study will include adolescents and adults who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems. Researchers will also evaluate the safety of MK-1406 and how well participants tolerate the study medicine.
الحالات
- Influenza
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 12 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | PREVENTION |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 10,000 مشارك |
الجهة الراعية والمتعاونون
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) الجهة الراعية
الأذرع والتدخلات
- MK-1406EXPERIMENTAL
Participants will receive 450 milligrams (mg) dose of MK-1406 (CD388) by subcutaneous (SC) injection.
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo by SC injection.
التدخلات
- منتج مركّب MK-1406
MK-1406 liquid for injection administered subcutaneously (SC)
- منتج مركّب Placebo
MK-1406 matched liquid for SC injection
مقاييس النتائج
مقياس النتيجة الأولي
Number of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of participants experiencing protocol-defined ILI occurring after administration of MK-1406 (CD388), with influenza infection confirmed by an RT-PCR+ result based on a NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
الإطار الزمني Up to approximately 24 weeks post dose
مقياس النتيجة الثانوي
Number of participants with ≥1 Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with ≥1 AE will be assessed.
الإطار الزمني Up to approximately Day 197
مقياس النتيجة الثانوي
Number of Participants Who Discontinued from the Study Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued the study because of an AE will be assessed.
الإطار الزمني Up to approximately Day 197
مقياس النتيجة الثانوي
Number of Participants with Injection Site Reactions (ISRs)
Participants will complete the injection site reaction questionnaire in the eDiary Day 1 through Day 8 following the study intervention administration to assess for reactogenicity, based on the US Food and Drug Administration (FDA) toxicity grading scale used for vaccine trials. Injection site reactions are graded on a scale from 1 to 5 where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe and Grade 4 is potentially life threatening. The injection-site reactions assessed are pain, tenderness, erythema/redness, and induration/swelling.
الإطار الزمني Up to approximately Day 8 post dose
مقياس النتيجة الثانوي
Number of Stratum B Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of Stratum B ((immunocompromised participants) experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by an RT-PCR+ result based on an NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
الإطار الزمني Up to approximately 24 weeks post dose
مقياس النتيجة الثانوي
Number of Participants with All-cause Hospitalization within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Hospitalizations are defined as an overnight admission in a hospital or similar acute care facility, including emergency rooms due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration. Number of participants with all-cause hospitalization within 30 days after the onset of symptomatic influenza will be assessed.
الإطار الزمني Up to 30 days after onset of symptomatic laboratory-confirmed influenza
مقياس النتيجة الثانوي
Number of Participants with All-cause Mortality within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Number of participants with mortality due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration will be determined.
الإطار الزمني Up to 30 days after onset of symptomatic laboratory-confirmed influenza
مقياس النتيجة الثانوي
Plasma Concentrations Following Administration of MK-1406 (CD388)
Blood samples will be collected at multiple time points to assess the plasma concentrations of MK-1406.
الإطار الزمني Day 1 (pre-dose), Day 29, and Day 197 post dose
مقياس النتيجة الثانوي
Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADAs)
The number of participants with confirmed anti MK-1406 antibodies post-baseline (i.e. treatment-emergent ADAs) will be determined via evaluation of blood samples collected at multiple time points.
الإطار الزمني Day 1 (pre-dose), Day 29, and Day 197 post dose
مقياس النتيجة الثانوي
Number of Participants with Treatment Boosted ADAs
The number of participants with an increase in ADA titer over an initial positive baseline titer (i.e., treatment-boosted ADAs) will be determined will be determined via evaluation of blood samples collected at multiple time points.
الإطار الزمني Day 1 (pre-dose), Day 29, and Day 197 post dose
التواريخ
| تاريخ البدء | 25 سبتمبر 2025 (فعلي) |
|---|---|
| الإتمام الأولي | 2 يوليو 2027 (تقديري) |
| الإتمام | 2 يوليو 2027 (تقديري) |
| أول نشر | 8 سبتمبر 2025 (فعلي) |
| آخر تحديث | 17 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | نوفمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
93 موقعاً قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| CINME - Centro de Investigaciones Metabólicas ( Site 0007) | Buenos Aires | Buenos Aires F.D. | نشط، دون تجنيد |
| Centro de Estudios Infectológicos S.A. ( Site 0002) | CABA | Buenos Aires | نشط، دون تجنيد |
| Equipo Ciencia ( Site 0008) | Ciudad Autonoma de Buenos Aires | Buenos Aires | نشط، دون تجنيد |
| Sanatorio Mayo Privado S.A ( Site 0003) | Córdoba | Córdoba Province | نشط، دون تجنيد |
| Centro Medico de Enfermedades Respiratorias ( Site 0005) | Florida | Buenos Aires | نشط، دون تجنيد |
| Instituto del Buen Aire ( Site 0006) | Santa Fe | نشط، دون تجنيد |
Australia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Emeritus Research ( Site 0106) | Botany | New South Wales | نشط، دون تجنيد |
| Core Research Group ( Site 0102) | Brisbane | Queensland | نشط، دون تجنيد |
| Emeritus Research ( Site 0101) | Camberwell | Victoria | نشط، دون تجنيد |
| Australian Clinical Research Network ( Site 0103) | Maroubra | New South Wales | نشط، دون تجنيد |
| The AIM Centre Hunter Diabetes Centre ( Site 0105) | Newcastle | New South Wales | نشط، دون تجنيد |
| Momentum St Leonards ( Site 0107) | St Leonards | New South Wales | نشط، دون تجنيد |
| Momentum Clinical Research Taringa ( Site 0104) | Taringa | Queensland | نشط، دون تجنيد |
Japan
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Takeuchi Hospital ( Site 0818) | Arakawa City | Tokyo | قيد التجنيد |
| Ishikawa Prefectural Central Hospital ( Site 0814) | Kanazawa | Ishikawa-ken | قيد التجنيد |
| Medical Corporation Chiyukai Shin Komonji Hospital ( Site 0820) | Kitakyushu | Fukuoka | قيد التجنيد |
| National Hospital Organization Tokyo National Hospital ( Site 0802) | Kiyose | Tokyo | قيد التجنيد |
| National Hospital Organization Kumamoto Medical Center ( Site 0801) | Kumamoto | قيد التجنيد | |
| Jobu Hospital for Respiratory Diseases ( Site 0821) | Maebashi | Gunma | قيد التجنيد |
| Maebashi Hirosegawa Clinic ( Site 0804) | Maebashi | Gunma | قيد التجنيد |
| National Hospital Organization Tokyo Medical Center ( Site 0807) | Meguro City | Tokyo | قيد التجنيد |
| Association of Healthcare Corporation Oyama East Clinic ( Site 0823) | Oyama | Tochigi | قيد التجنيد |
| NewHeart Watanabe Institute ( Site 0811) | Suginami | Tokyo | قيد التجنيد |
South Africa
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Josha Research ( Site 0216) | Bloemfontein | Free State | نشط، دون تجنيد |
| Madibeng Centre for Research ( Site 0201) | Brits | North West | نشط، دون تجنيد |
| TREAD Research ( Site 0206) | Cape Town | Western Cape | نشط، دون تجنيد |
| TASK Applied Science - Headquarter ( Site 0211) | Cape Town | Western Cape | نشط، دون تجنيد |
| Tiervlei Trial Centre ( Site 0204) | Cape Town | Western Cape | نشط، دون تجنيد |
| Centre for the Aids Programme of Research in South Africa. CAPRISA ( Site 0220) | Durban | KwaZulu-Natal | نشط، دون تجنيد |
| Synergy Biomed Research Institute ( Site 0218) | East London | Eastern Cape | نشط، دون تجنيد |
| Ubuntu Clinical Research Center ( Site 0208) | Johannesburg | Gauteng | نشط، دون تجنيد |
| Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0205) | Johannesburg | Gauteng | نشط، دون تجنيد |
| Qhakaza Mbokodo Research Clinic ( Site 0215) | Ladysmith | KwaZulu-Natal | نشط، دون تجنيد |
| Newtown Clinical Research Centre ( Site 0207) | Newtown | Gauteng | نشط، دون تجنيد |
| Paarl Research Centre ( Site 0213) | Paarl | Western Cape | نشط، دون تجنيد |
| Jose Pearson TB Hospital ( Site 0202) | Port Elizabeth | Eastern Cape | نشط، دون تجنيد |
| Global Clinical Trials ( Site 0212) | Pretoria | Gauteng | نشط، دون تجنيد |
| Emmed Research Incorporating ( Site 0209) | Pretoria | Gauteng | نشط، دون تجنيد |
| Jongaie Research ( Site 0214) | Pretoria West | Gauteng | نشط، دون تجنيد |
| Aurum Institute - Rustenburg ( Site 0203) | Rustenburg | North West | نشط، دون تجنيد |
| Welkom Clinical Trial Centre ( Site 0219) | Welkom | Free State | نشط، دون تجنيد |
United Kingdom
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Aberdeen Royal Infirmary ( Site 0423) | Aberdeen | Aberdeen City | قيد التجنيد |
| Birmingham Heartlands Hospital ( Site 0440) | Birmingham | قيد التجنيد | |
| Queen Elizabeth Hospital ( Site 0411) | Birmingham | نشط، دون تجنيد | |
| Layton Medical Centre ( Site 0405) | Blackpool | Lancashire | قيد التجنيد |
| Bradford Royal Infirmary ( Site 0444) | Bradford | قيد التجنيد | |
| Royal Sussex County Hospital ( Site 0443) | Brighton | Brighton And Hove | قيد التجنيد |
| Southmead Hospital ( Site 0409) | Bristol | Bristol, City of | نشط، دون تجنيد |
| Velocity Clinical Research, Bristol ( Site 0428) | Bristol | Bristol, City of | قيد التجنيد |
| University Hospital of Wales ( Site 0420) | Cardiff | Wales | نشط، دون تجنيد |
يُدرَج 161 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 13 نوفمبر 2026
تأخّر تاريخ الإتمام
Primary completion delayed 2 days
2027-06-302027-07-02
- 6 نوفمبر 2026
أُضيف موقع
26 sites added (211 total)
185211
- 27 أكتوبر 2026
أُضيف موقع
4 sites added (185 total)
181185
- 15 أكتوبر 2026
أُزيل موقع
181 sites removed (181 total)
362181
- 15 أكتوبر 2026
تغيّرت الحالة
Status changed from Active not recruiting to Recruiting
ACTIVE_NOT_RECRUITINGRECRUITING
- 15 أكتوبر 2026
فُتح التجنيد
Recruitment opened
ACTIVE_NOT_RECRUITINGRECRUITING
- 17 سبتمبر 2026
تأخّر تاريخ الإتمام
Primary completion delayed 29 days
2027-06-012027-06-30
- 17 سبتمبر 2026
أُضيف موقع
181 sites added (362 total)
181362